Scotch Plains, NJ, United States of America

Emma R Parmee

This inventor holds 43 USPTO granted patents and 6 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Dipeptidyl Peptidase Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc.. Active years: 1995-2017.

USPTO Granted Patents = 43 (Patent Applications = 6)

% Patents Active = 83.7

CIPO Patents = 6

EPO Patents = 13 (Patent Applications = 9)

Average Co-Inventor Count = 4.7

ph-index = 12

Forward Citations = 435(Granted Patents)

Location History:

Hoboken, NJ (US) (1995 - 1998)
Highland Park, NJ (US) (2000)
Scotch Plains, NJ (US) (2000 - 2014)
Doylestown, PA (US) (2013 - 2017)

Company Filing History:

23 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 1995-2017

Loading Chart...

Areas of Expertise:

Dipeptidyl Peptidase Inhibitors

Glucagon Receptor Antagonists

Soluble Guanylate Cyclase Activators

Beta-Amino Heterocyclic Compounds

Pyrazole Derivatives

Fused Indoles

Acyl Indoles

2-Pyridinecarboxamide Derivatives

Cyclohexylglycine Derivatives

Compositions

Methods of Treatment

Type 2 Diabetes

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9649294 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2017-05-16),

2. 9527838 - 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment (2016-12-27),

3. 9453038 - Glucokinase activator compounds, compositions containing such compounds, and methods of treatment (2016-09-27),

4. 9365574 - Soluble guanylate cyclase activators (2016-06-14),

5. 9359339 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2016-06-07),

6. 8809579 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2014-08-19),

7. 8741910 - Soluble guanylate cyclase activators (2014-06-03),

8. 8507512 - Soluble guanylate cyclase activators (2013-08-13),

9. 8455638 - Soluble guanylate cyclase activators (2013-06-04),

10. 8445538 - Glucagon receptor antagonist compounds (2013-05-21),

11. 8440668 - Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes (2013-05-14),

12. 8436015 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2013-05-07),

13. 8324384 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2012-12-04),

14. 8318760 - Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use (2012-11-27),

15. 8318667 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2012-11-27),

Title: Unveiling the Ingenious Inventor Emma R Parmee

Introduction

Emma R Parmee, a brilliant inventor hailing from Scotch Plains, NJ, has left an indelible mark in the field of pharmaceutical innovations. With an impressive portfolio of 43 patents, Parmee's groundbreaking work has significantly contributed to advancements in treating type 2 diabetes and related conditions.

Latest Patents

Parmee's recent patents showcase her commitment to developing cutting-edge solutions for medical challenges. One of her latest inventions includes Glucagon receptor antagonist compounds, known for their long duration of action and efficacy in managing type 2 diabetes. Additionally, her research on 2-pyridinecarboxamide derivatives has paved the way for novel treatments targeting glucokinase activation in diabetes patients.

Career Highlights

Having worked at renowned companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc., Parmee has demonstrated her expertise in translating scientific discoveries into tangible solutions. Her innovative approach and dedication to improving patient outcomes have earned her accolades within the pharmaceutical industry.

Collaborations

Parmee's collaborative efforts with accomplished professionals like Ann E Weber and Ronald M Kim have fostered a culture of innovation and excellence. By synergizing their expertise, they have been instrumental in bringing forth novel pharmaceutical compositions and treatment methods for complex medical conditions.

Conclusion

In conclusion, Emma R Parmee's trailblazing work in the field of pharmaceutical inventions continues to redefine the landscape of diabetes treatment. Her relentless pursuit of innovation, coupled with her exceptional collaborations, reaffirms her status as a visionary inventor committed to shaping a healthier future for all.